JP6482552B2 - 界面活性剤および多価アルコールを有さず直ちに湿潤可能な経口フィルム剤形 - Google Patents

界面活性剤および多価アルコールを有さず直ちに湿潤可能な経口フィルム剤形 Download PDF

Info

Publication number
JP6482552B2
JP6482552B2 JP2016530631A JP2016530631A JP6482552B2 JP 6482552 B2 JP6482552 B2 JP 6482552B2 JP 2016530631 A JP2016530631 A JP 2016530631A JP 2016530631 A JP2016530631 A JP 2016530631A JP 6482552 B2 JP6482552 B2 JP 6482552B2
Authority
JP
Japan
Prior art keywords
film
oral film
copolymer
oral
vinylpyrrolidone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016530631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527262A5 (enExample
JP2016527262A (ja
Inventor
オルスト・ジ・ゼルブ
アンジェラ・アングスティ
ナディーヌ・ペマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IntelGenx Corp
Original Assignee
IntelGenx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52428223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6482552(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by IntelGenx Corp filed Critical IntelGenx Corp
Publication of JP2016527262A publication Critical patent/JP2016527262A/ja
Publication of JP2016527262A5 publication Critical patent/JP2016527262A5/ja
Application granted granted Critical
Publication of JP6482552B2 publication Critical patent/JP6482552B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016530631A 2013-07-31 2014-07-30 界面活性剤および多価アルコールを有さず直ちに湿潤可能な経口フィルム剤形 Expired - Fee Related JP6482552B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361860345P 2013-07-31 2013-07-31
US61/860,345 2013-07-31
PCT/IB2014/002047 WO2015015303A2 (en) 2013-07-31 2014-07-30 Instantly wettable oral film dosage form without surfactant or polyalcohol

Publications (3)

Publication Number Publication Date
JP2016527262A JP2016527262A (ja) 2016-09-08
JP2016527262A5 JP2016527262A5 (enExample) 2017-09-07
JP6482552B2 true JP6482552B2 (ja) 2019-03-13

Family

ID=52428223

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016530631A Expired - Fee Related JP6482552B2 (ja) 2013-07-31 2014-07-30 界面活性剤および多価アルコールを有さず直ちに湿潤可能な経口フィルム剤形

Country Status (18)

Country Link
US (1) US9301948B2 (enExample)
EP (2) EP3427732A1 (enExample)
JP (1) JP6482552B2 (enExample)
KR (1) KR102272442B1 (enExample)
CN (1) CN105530921B (enExample)
AU (1) AU2014298130A1 (enExample)
BR (1) BR112016002074B1 (enExample)
CA (1) CA2919442A1 (enExample)
CL (1) CL2016000160A1 (enExample)
DK (1) DK3027179T3 (enExample)
ES (1) ES2706481T3 (enExample)
HK (1) HK1222796A1 (enExample)
IL (1) IL243651A0 (enExample)
MX (1) MX366595B (enExample)
RU (1) RU2016106907A (enExample)
SG (1) SG11201600455XA (enExample)
WO (1) WO2015015303A2 (enExample)
ZA (1) ZA201600785B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160220480A1 (en) * 2015-02-03 2016-08-04 Intelgenx Corp. Oral dosage film exhibiting enhanced mucosal penetration
KR20230137362A (ko) 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
CN105997955B (zh) 2016-06-28 2017-09-12 力品药业（厦门）有限公司 一种帕洛诺司琼口腔膜剂及其制备方法
KR101802183B1 (ko) * 2016-11-16 2017-11-28 주식회사 유영제약 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물
CA3076815A1 (en) * 2017-09-27 2019-04-04 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
DE102017127452A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag Wasserlösliche Polymerklebschichten
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
US12303501B2 (en) 2018-11-05 2025-05-20 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US12440472B2 (en) 2021-06-16 2025-10-14 Intelgenx Corp. Stable tryptamine oral films
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
JP3460538B2 (ja) * 1997-10-08 2003-10-27 救急薬品工業株式会社 速溶性フィルム製剤
US7027414B2 (en) * 2001-08-09 2006-04-11 Hughes Network Systems, Llc Method, apparatus, and system for identifying and efficiently treating classes of traffic
WO2005040228A2 (en) 2003-10-24 2005-05-06 Adhesives Research, Inc. Disintegratable films for diagnostic devices
CN102764247B (zh) * 2004-01-30 2016-04-20 考里安国际公司 递送活性剂的快速溶解膜
US20050281757A1 (en) * 2004-06-17 2005-12-22 Sayed Ibrahim Oral care film
US20100266669A1 (en) * 2007-12-11 2010-10-21 Novartis Ag Multi-zone films
ES2592882T3 (es) * 2008-10-14 2016-12-02 Mcneil Ab Forma de dosificación intra-oral de múltiples porciones y uso de la misma
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
US20100285130A1 (en) * 2009-05-06 2010-11-11 Monosol Rx, Llc Coating of complexed actives in film formulations
JP2013511565A (ja) * 2009-11-24 2013-04-04 ビーエーエスエフ ソシエタス・ヨーロピア フィルム様医薬剤形
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
JP2012031164A (ja) * 2010-07-06 2012-02-16 Teika Seiyaku Kk フィルム状製剤
JP5587168B2 (ja) * 2010-12-28 2014-09-10 花王株式会社 医療器具用洗浄剤組成物
CN103429223A (zh) * 2011-01-17 2013-12-04 武田药品工业株式会社 口腔分散片
KR101303479B1 (ko) * 2011-07-28 2013-09-06 (주)씨엘팜 가식성 필름형성 조성물 및 약물이 함유된 가식성 필름형 제제
MX370064B (es) * 2013-05-10 2019-11-29 Ctc Bio Inc Preparación de película que contiene donepezilo en su forma de base libre y método para producirla.

Also Published As

Publication number Publication date
DK3027179T3 (en) 2019-02-11
AU2014298130A1 (en) 2016-02-11
BR112016002074A2 (pt) 2017-08-01
KR102272442B1 (ko) 2021-07-02
CN105530921A (zh) 2016-04-27
MX2016001399A (es) 2016-10-28
EP3027179A4 (en) 2017-02-22
BR112016002074B1 (pt) 2023-01-24
EP3027179B1 (en) 2018-10-17
KR20160089335A (ko) 2016-07-27
SG11201600455XA (en) 2016-02-26
US20150038540A1 (en) 2015-02-05
EP3427732A1 (en) 2019-01-16
ES2706481T3 (es) 2019-03-29
CA2919442A1 (en) 2015-02-05
CL2016000160A1 (es) 2016-11-18
HK1222796A1 (zh) 2017-07-14
EP3027179A2 (en) 2016-06-08
WO2015015303A2 (en) 2015-02-05
MX366595B (es) 2019-07-15
US9301948B2 (en) 2016-04-05
CN105530921B (zh) 2021-02-26
ZA201600785B (en) 2017-04-26
IL243651A0 (en) 2016-02-29
WO2015015303A3 (en) 2015-05-21
JP2016527262A (ja) 2016-09-08
RU2016106907A (ru) 2017-09-01

Similar Documents

Publication Publication Date Title
JP6482552B2 (ja) 界面活性剤および多価アルコールを有さず直ちに湿潤可能な経口フィルム剤形
JP6545839B2 (ja) 口腔内崩壊錠及びその製造方法
JP6294479B2 (ja) 経口分散性フィルム
JP5537943B2 (ja) 速崩壊性固形製剤
EP2308511B1 (en) Tablet quickly disintegrating in the oral cavity and method for producing the same
AU2007227614B2 (en) Solid dosage form containing a taste masked active agent
KR101188594B1 (ko) 쓴맛이 차단된 실데나필 시트르산의 구강내 속붕해 필름제형
HUE031175T2 (en) Nicotine-containing square tablet formulations
JP2003034655A (ja) 速崩壊性固形製剤
JP5337430B2 (ja) 口腔内速崩壊錠
JP2010241760A (ja) 不快な味の軽減された口腔内速崩壊錠及びその製造方法
WO2010119851A1 (ja) 口腔内崩壊錠
EP2931257B1 (fr) Comprimes orodispersibles obtenus par compression moulage
TWI383809B (zh) 含有西洛他唑（ｃｉｌｏｓｔａｚｏｌ）之口腔崩解粉末
KR101953735B1 (ko) 포스포다이에스터라제-5 억제제를 포함하는 츄정
JP6838632B2 (ja) 固形製剤
WO2017188361A1 (ja) トスフロキサシントシル酸塩を含む錠剤
JP2024053372A (ja) コーティング剤、及び口腔内崩壊性錠剤の錠剤物性の安定化法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190212

R150 Certificate of patent or registration of utility model

Ref document number: 6482552

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees